Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED WITH NOVEL ADJUVANTS IN HEALTHY ADULTS

NCT05805826 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05805826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05805826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED WITH NOVEL ADJUVANTS IN HEALTHY ADULTS
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 23, 2023
Completion date
June 19, 2031
Enrollment
936 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

clostridoides difficile associated disease